tbuckley/cabot-search huggingface dataset:
Baby and Bathwater—A Telehealth Tale
Authors: Richard C. Wasserman
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
P-264 Clinical validation of next-generation sequencing as a liquid biopsy for the monitoring of patients with metastatic colorectal cancer
Authors: G. Zarkavelis, M. Kastrisiou, E. Papadopoulou, G. Nasioulas, E. Tselikou, A. Mantziou, C. Tzallas, A. Batistatou, A. Magklara, G. Pentheroudakis
Journal: Annals of Oncology (2020)
SW620ヒト結腸癌細胞におけるG 2 -M停止からのスタウロスポリンで誘導されるアポトーシスの分離 アポトーシスカスケードの開始はミトコンドリア膜電位(Δψ m )の上昇と関連する
Authors: Heerdt B G, Houston M A, Mariadason J M, Augenlicht L H
Journal: Cancer Research (2000)
Bundled intervention to improve patient safety by reducing skin specimen–related errors in a tertiary dermatology practice
Authors: Ashley N. Privalle, Dawn M.R. Davis, Megha M. Tollefson, Joseph M. Doppler, Scott Welder, Jennifer A. Morris-Kidd, Brittney S. Peterson, Nneka I. Comfere
Journal: Journal of the American Academy of Dermatology (2020)
SO-9 Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo
Authors: A. El-Khoueiry, T. Meyer, A. Cheng, L. Rimassa, S. Sen, S. Milwee, R. Kelley, G. Abou-Alfa
Journal: Annals of Oncology (2020)
Relationship Between Perceptions of Treatment Goals and Psychological Distress in Patients With Advanced Cancer
Authors: Areej El-Jawahri, Deborah Forst, Alyssa Fenech, Keri O. Brenner, Amanda L. Jankowski, Lauren Waldman, Isabella Sereno, Ryan Nipp, Joseph A. Greer, Lara Traeger, Vicki Jackson, Jennifer Temel
Journal: Journal of the National Comprehensive Cancer Network (2020)

Studies have shown gaps in prognostic understanding among patients with cancer. However, few studies have explored patients' perceptions of their treatment goals versus how they perceive their oncologist's goals, and the association of these views with their psychological distress.We conducted a cross-sectional study of 559 patients with incurable lung, gastrointestinal, breast, and brain cancers. The Prognosis and Treatment Perception Questionnaire was used to assess patients' reports of their treatment goal and their oncologist's treatment goal, and the Hospital Anxiety and Depression Scale was used to assess patients' psychological symptoms.We found that 61.7% of patients reported that both their treatment goal and their oncologist's treatment goal were noncurative, whereas 19.3% reported that both their goal and their oncologist's goal were to cure their cancer, 13.9% reported that their goal was to cure their cancer whereas their oncologist's goal was noncurative, and 5% reported that their goal was noncurative whereas their oncologist's goal was curative. Patients who reported both their goal and their oncologist's goal as noncurative had higher levels of depression (B=0.99; P=.021) and anxiety symptoms (B=1.01; P=.015) compared with those who reported that both their goal and their oncologist's goal was curative. Patients with discordant perceptions of their goal and their oncologist's goal reported higher anxiety symptoms (B=1.47; P=.004) compared with those who reported that both their goal and their oncologist's goal were curative.One-fifth of patients with incurable cancer reported that both their treatment goal and their oncologist's goal were to cure their cancer. Patients who acknowledged the noncurative intent of their treatment and those who perceived that their treatment goal was discordant from that of their oncologist reported greater psychological distress.
P-62 Inferior survival for mismatch repair deficient metastatic colorectal cancer observed in an Irish cohort
Authors: A. Talbot, O. Cathal, D. Gallagher, R. Ward, S. Finn, P. Williams, C. Nolan, R. Clarke, E. Berkeley, C. Peyton, C. Giffney
Journal: Annals of Oncology (2020)
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension
Authors: Marie-Camille Chaumais, Mohamed Reda Amar Djessas, Raphaël Thuillet, Amélie Cumont, Ly Tu, Guillaume Hebert, Pauline Gaignard, Alice Huertas, Laurent Savale, Marc Humbert, Christophe Guignabert
Journal: Cardiovascular Research (2020)

Although right ventricular (RV) function is an important determinant of morbidity and mortality in patients with pulmonary arterial hypertension (PAH), there is no treatment targeting directly the RV. We evaluate the efficacy of sacubitril/valsartan (LCZ 696) as add-on therapy to bosentan in rats with severe pulmonary hypertension (PH).
Abstract 16840: A Community Engagement Initiative Supporting a Culture of Heart Health
Authors: Annette Jakubisin Konicki
Journal: Circulation (2018)

Background: Historically seen as a man’s disease, coronary heart disease (CHD) is the annual cause of death for approximately the same number of women as men. Strides have been made in raising awareness of women’s CHD risk, and national initiatives call for programs that both raise awareness and sustain engagement in heart healthy lifestyles. A gap remains between women’s personal awareness of risk and the preventative activities in which they engage. Purpose/Methods: Embracing the concept of cardiovascular health (CVH) from the American Heart Association’s Impact Goal, a coalition of community organizations partnered to launch a three pronged community engagement initiative (CEI): Follow the Fifty: Models of Heart Health . The purpose was to: raise women’s awareness of their risks for CHD; raise women’s CVH awareness, and increase women’s knowledge of evidence based activities that promote and support a culture of heart health through reducing cardiovascular risk factors (CVRF). Women participants (N=177), recruited through community advertising, became “Models of Heart Health.” The nine month CEI provided presentations on stress reduction, CVD awareness, and CVRF reduction activities; community gardens for growing heart healthy foods; and coaches paired with Models to support reducing individual CVRF. Community businesses provided CVH options: heart healthy menu choices, gym classes/memberships, group training activities. Baseline biometric data screened Models for participation (weight, BMI, blood pressure, glucose, smoking status). Models completed self-report surveys describing nutrition, physical activity, and stress management behavior changes resulting from the CEI. Focus groups were held to gather qualitative feedback. Results/Conclusions: Follow the Fifty CEI successfully raised women’s awareness of their risk for CVD and influenced personal behavior change to reduce CVRF, thereby promoting and sustaining heart health. Models reported adopting improved diet (93.6%), physical activity (84.6%), and stress management activities (52.5%). Focus groups identified themes of: “goal driven with accountability,” “ongoing process,” “being rewarded,” a sense of “sisterhood/enduring friendships,” “empowerment,” and “confidence to attain goals.” Providing women with a mechanism for decision support and self-management, while identifying and strengthening the link to community resources resulted in adoption of effective therapeutic CVD preventive behaviors, creating a culture of heart health.
US withdrawal from WHO is unlawful and threatens global and US health and security
Authors: Lawrence O Gostin, Harold Hongju Koh, Michelle Williams, Margaret A Hamburg, Georges Benjamin, William H Foege, Patricia Davidson, Elizabeth H Bradley, Michele Barry, Jeffrey P Koplan, Mirta Flia Roses Periago, Wafaa El Sadr, Ann Kurth, Sten H Vermund, Matthew M Kavanagh
Journal: The Lancet (2020)
Changed Primary Outcome Between Trial Registration and Publication—Reply
Authors: Raymond F. Anton, Michaela Hoffman
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
P-301 Gastrointestinal stromal tumors: 10 years of experience in the medical oncology department at Mohammed VI university hospital in Marrakech, Morocco
Authors: M. Kaakoua, N. Benhima, K. Cisse, H. Jouihri, S. Lalaoui Rachidi, M. Layachi, M. Elfadli, I. Essadi, R. Belbaraka
Journal: Annals of Oncology (2020)
P-38 KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Authors: J. Tabernero, Y. Bang, E. Van Cutsem, C. Fuchs, Y. Janjigian, P. Bhagia, K. Li, D. Adelberg, S. Qin
Journal: Annals of Oncology (2020)
P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer
Authors: D. Catenacci, M. Koshiji Rosales, H. Chung, H. Yoon, L. Shen, M. Moehler, Y. Kang
Journal: Annals of Oncology (2020)
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
Authors: Valeria Santini, Pierre Fenaux, Aristoteles Giagounidis, Uwe Platzbecker, Alan F. List, Torsten Haferlach, Jim Zhong, Chengqing Wu, Konstantinos Mavrommatis, C. L. Beach, Kyle J. MacBeth, Antonio Almeida
Journal: Leukemia (2020)
O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Authors: H. Yoon, C. Fuchs, M. Özgüroğlu, Y. Bang, M. Di Bartolomeo, M. Mandala, M. Ryu, L. Fornaro, T. Olesinski, C. Caglevic, H. Chung, K. Muro, E. Van Cutsem, A. Elme, P. Thuss-Patience, I. Chau, A. Ohtsu, A. Wang, P. Bhagia, J. Lin, C. Shih, K. Shitara
Journal: Annals of Oncology (2020)
P-232 Clinical outcomes and characteristics according to localization of colorectal cancer in Fundacion Santa Fe De Bogota between May 2015-May 2019
Authors: L. Pino Villareal, I. Triana Avellaneda, A. Ospina Serrano, N. Caballero, J. Segovia, C. Gonzalez
Journal: Annals of Oncology (2020)
Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
Authors: Nazli Dizman, Yung Lyou, Nicholas Salgia, Paulo Gustavo Bergerot, JoAnn Hsu, Daniel Enriquez, Tyler Izatt, Jeffrey M Trent, Sara Byron, Sumanta Pal
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background The clinical significance of tumor-specific genomic alterations in metastatic renal cell carcinoma (mRCC) is emerging, with several studies suggesting an association between PBRM1 mutations and response with immunotherapy (IO). We sought to determine genomic predictors of differential response to vascular endothelial growth factor–tyrosine kinase inhibitors (VEGF-TKIs) and IO. Methods Consecutive patients who underwent genomic profiling were identified; patients receiving either VEGF-TKIs or IO were included. Clinical tumor-normal whole exome sequencing and tumor whole transcriptome sequencing test were performed using a Clinical Laboratory Improvement Amendments (CLIA)-certified assay (Ashion Analytics; Phoenix, Arizona, USA). Genomic findings were compared between patients with clinical benefit (CB; complete/partial response or stable disease for &gt;6 months) and no clinical benefit (NCB) in VEGF-TKI-treated patient cohort and IO-treated patient cohort. Results 91 patients received genomic profiling and 58 patients received VEGF-TKI and/or IO therapy. 17 received sequenced treatment involving both VEGF-TKI and IO, resulting in 32 patients in the IO cohort and 43 patients in the VEGF-TKI cohort. The most commonly used IO and VEGF-TKIs were nivolumab (66%) and sunitinib (40%). The most frequently detected alterations in the overall cohort were in VHL (64%), PBRM1 (38%), SETD2 (24%), KDM5C (17%) and TERT (12%). TERT promoter mutations were associated with NCB in the IO cohort (p=0.038); transcriptomic analysis revealed multiple differentially regulated pathways downstream of TERT. TERT promoter mutations and PBRM1 mutations were found to be mutually exclusive. While PBRM1 mutations were more prevalent in patients with CB with IO and VEGF-TKIs, no statistically significant association was found. Conclusions Our analysis found that TERT promoter mutations may be a negative predictor of outcome with IO and are mutually exclusive with PBRM1 loss-of-function mutations.
Non-invasive ventilation deaths fell for first time in 2019, audit finds
Authors: Elisabeth Mahase
Journal: BMJ (2020)

Inpatient mortality among people receiving non-invasive ventilation (NIV) has decreased for the first time since 2010, falling from 34% in 2013 to 26% in 2019, figures released by the British Thoracic Society show.

The annual National Adult Non-Invasive Ventilation audit,1 which began in 2010, reported “substantial improvements in processes of care and patient outcomes” in 2019 when compared with previous years.

“Some improvement in overall mortality may be attributed to improved patient selection,” it said. “Mortality outcomes were lower for each diagnostic category, and most notably for patients with COPD [chronic obstructive pulmonary disease] and obesity-related respiratory failure.”

The 2019 audit included data collected in February and March 2019 from more than 150 hospitals, involving over 3500 patient …
LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
Authors: A. Grothey, J. Tabernero, J. Taieb, R. Yaeger, T. Yoshino, E. Maiello, E. Elez Fernandez, A. Ruiz Casado, P. Ross, T. André, T. Kato, J. Ruffinelli, J. Graham, M. Van den Eynde, R. Vera, B. Jean, E. Carriere Roussel, C. Cahuzac, Z. Issiakhem, J. Vedovato, E. Van Cutsem
Journal: Annals of Oncology (2020)
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
Authors: Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Bernard Escudier, Frede Donskov, Robert Hawkins, Sergio Bracarda, Jens Bedke, Ugo De Giorgi, Camillo Porta, Alain Ravaud, Francis Parnis, Enrique Grande, Wei Zhang, Mahrukh Huseni, Susheela Carroll, Roxana Sufan, Christina Schiff, Michael B. Atkins
Journal: European Urology (2020)
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab
Authors: Anne Hu, Paulo Gustavo Kotze, Alice Burgevin, Willam Tan, Alison Jess, Pei-Shun Li, Karen Kroeker, Brendan Halloran, Remo Panaccione, Laurent Peyrin-Biroulet, Christopher Ma, Ashwin N. Ananthakrishnan
Journal: Clinical Gastroenterology and Hepatology (2020)
O-15 The dark age of single organ screening is over: CD24 is a novel universal simple blood test for early detection of cancer
Authors: S. Shapira, D. Kazanov, M. Ben Shimon, M. Hay Levy, F. Mdah, S. Asido, N. Carmel, O. Yossepowitch, D. Grisaru, D. Fliss, O. Isakov, G. Lahat, I. Nachmany, N. Gluck, M. Peer, I. Wolf, N. Arber
Journal: Annals of Oncology (2020)
Prevention strategies to reduce future impact of low back pain: a systematic review and meta-analysis
Authors: Tarcisio F de Campos, Chris G Maher, Joel T Fuller, Daniel Steffens, Stephanie Attwell, Mark J Hancock
Journal: British Journal of Sports Medicine (2020)

Objective To evaluate the evidence from randomised controlled trials (RCTs) on the effectiveness of prevention strategies to reduce future impact of low back pain (LBP), where impact is measured by LBP intensity and associated disability. Design Systematic review with meta-analysis. Data sources MEDLINE, Embase, CINAHL, PEDro and The Cochrane (CENTRAL) databases from inception to 22 October 2018. Eligibility criteria RCTs evaluating any intervention aiming to prevent future impact of LBP, reporting an outcome measure of LBP intensity and/or disability measured at least 3 months post-randomisation, and the intervention group must be compared with a group that received no intervention/placebo or minimal intervention. Trials restricting recruitment to participants with current LBP were excluded. Results 27 published reports of 25 different trials including a total of 8341 participants fulfilled the inclusion criteria. The pooled results, from three RCTs (612 participants), found moderate-quality evidence that an exercise programme can prevent future LBP intensity (mean difference (MD) −4.50; 95% CI −7.26 to −1.74), and from 4 RCTs (471 participants) that an exercise and education programme can prevent future disability due to LBP (MD −6.28; 95% CI −9.51 to −3.06). It is uncertain whether prevention programmes improve future quality of life (QoL) and workability due to the overall low-quality and very low-quality available evidence. Conclusions This review provides moderate-quality evidence that an exercise programme, and a programme combining exercise and education, are effective to reduce future LBP intensity and associated disability. It is uncertain whether prevention programmes can improve future QoL and workability. Further high-quality RCTs evaluating prevention programmes aiming to reduce future impact of LBP are needed.
SO-35 Tumor infiltrating CD3 lymphocytes and CD68 macrophages are associated with long-time survival in metastatic colorectal cancer patients treated with chemotherapy
Authors: K. Aasebø, J. Bruun, C. Bergsland, G. Eide, A. Dragomir, F. Ponten, M. Guren, A. Svindland, P. Pfeiffer, B. Glimelius, A. Sveen, A. Nesbakken, R. Lothe, H. Sorbye
Journal: Annals of Oncology (2020)
P-223 Prognostic role of inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy
Authors: A. Ioannou, S. Demiri, G. Papaxoinis, E. Sarris, E. Klouva, P. Baxevanos, G. Garefalakis, N. Pitsillos, A. Kyriakidou, I. Mavrogenis, G. Goumas, P. Gouveris, P. Kourakos, D. Trfonopoulos, G. Koumakis
Journal: Annals of Oncology (2020)
Abstract 16367: Cigarette Smoking in Patients With Heart Failure: A 20-Year Experience at Duke University Medical Center
Authors: Christopher Pumill, Angie Wu, Karen Chiswell, Linda Shaw, Robert J Mentz
Journal: Circulation (2018)

Background: Cigarette smoking is associated with incident heart failure, yet limited data are available exploring the association between smoking status and long-term outcomes in preserved vs. redu...
Abstract 15563: Study on the FBN1 Gene Mutation Spectrum in Chinese Patients With Marfan Syndrome and Association Between Genotype and Clinical Phenotype
Authors: Shijun Xu, Yuwei Fu, Hairui Sun, Jianbin Wang, Feng Lan, Yihua He, Hongjia Zhang
Journal: Circulation (2018)

Object: In this study, we sought to detect the FBN1 gene mutation spectrum in Chinese population with Marfan Syndromn (MFS) (OMIM #000138) and to investigate the correlations between the FBN1 gene ...
P-102 The impact of a multidisciplinary approach in the management of pancreatic disease
Authors: B. Di Stefano, G. Quero, C. Bagalà, F. Claudio, M. Bensi, R. Menghi, C. Cina, G. Mattiucci, R. Manfredi, F. Cellini, M. Brizi, F. D'Aversa, V. Perri, A. Larghi, F. Attili, F. Inzani, S. Alfieri, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2020)
VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses
Authors: Yilan Shen, Wei Chen, Lei Han, Qi Bian, Jiajun Fan, Zhonglian Cao, Xin Jin, Tao Ding, Zongshu Xian, Zhiyong Guo, Wei Zhang, Dianwen Ju, Xiaobin Mei
Journal: Acta Pharmaceutica Sinica B (2020)

Diabetic nephropathy (DN) is considered the primary causes of end-stage renal disease (ESRD) and is related to abnormal glycolipid metabolism, hemodynamic abnormalities, oxidative stress and chronic inflammation. Antagonism of vascular endothelial growth factor B (VEGF-B) could efficiently ameliorate DN by reducing renal lipotoxicity. However, this pharmacological strategy is far from satisfactory, as it ignores numerous pathogenic factors, including anomalous reactive oxygen species (ROS) generation and inflammatory responses. We found that the upregulation of VEGF-B and downregulation of interleukin-22 (IL-22) among DN patients were significantly associated with the progression of DN. Thus, we hypothesized that a combination of a VEGF-B antibody and IL-22 could protect against DN not only by regulating glycolipid metabolism but also by reducing the accumulation of inflammation and ROS. To meet these challenges, a novel anti-VEGFB/IL22 fusion protein was developed, and its therapeutic effects on DN were further studied. We found that the anti-VEGFB/IL22 fusion protein reduced renal lipid accumulation by inhibiting the expression of fatty acid transport proteins and ameliorated inflammatory responses via the inhibition of renal oxidative stress and mitochondrial dysfunction. Moreover, the fusion protein could also improve diabetic kidney disease by increasing insulin sensitivity. Collectively, our findings indicate that the bifunctional VEGF-B antibody and IL-22 fusion protein could improve the progression of DN, which highlighted a novel therapeutic approach to DN.
P-78 Early tumour shrinkage, depth of response and survival outcomes for RAS wild-type metastatic colorectal cancer patients classified by baseline tumour load: Retrospective pooled analysis of panitumumab PRIME/PEAK studies
Authors: F. Loupakis, M. Peeters, M. Geissler, D. Modest, M. Valladares-Ayerbes, T. Price, P. Burdon, Y. Zhang, J. Taieb
Journal: Annals of Oncology (2020)
P-305 Efficacy and safety of IMATINIB in gastrointestinal stromal tumors: Experience of the medical oncology department of the CHU Hassan II of Fez
Authors: L. Nouikh, S. Berrad, H. Erraichi, L. Amaadour, K. Oualla, Z. benbrahim, A. Samia, M. Nawfel
Journal: Annals of Oncology (2020)